Artificial intelligence in drug discovery

Artificial intelligence in drug discovery

The recent publication of papers by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) has spurred the debate on the use of artificial intelligence (AI) in drug development and how it can be used to bring novel compounds to the market.

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.


Not a TOPRA member yet? Join our global community.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Have you heard what you’re missing? Listen now to the RegRapPod podcast show, for free!